To Drive Asia Pacific Pregnancy & Ovulation Testing Market over the Forecast Period: Ken Research


A pregnancy test is used to verify if a woman is pregnant. Pregnancy test is done by analyzing a sample of a woman’s blood or urine for the presence of human chorionic gonadotropin (hCG). hCG is a hormone produced by placenta and is usually present in a woman’s body when she is pregnant. On the other hand, ovulation test is capable of detecting an uptick in luteinizing hormone (LH) to decide the most favorable time for conceiving children.

Asia Pacific Pregnancy & Ovulation Testing Market

According to study, “Asia Pacific Pregnancy & Ovulation Testing Market Research Report: By Type (hCG Detection, Ovulation Testing), by Mode of Purchase (OTC Testing, Prescription Testing), End-User (Hospitals & Clinics, Fertility Centers, Others) – Global Forecast Till 2023” the key companies that are currently working in the Asia Pacific pregnancy & ovulation testing market are Gregory Pharmaceutical Holdings, Inc., TaiDoc Technology & Corporation, Proctor & Gamble, Mankind Pharma Ltd., Fairhaven Health, LLC, Geratherm Medical AG, Quidel Corporation, Cadila Healthcare Limited, SPD Swiss Precision Diagnostics GmbH, Piramal Enterprises Ltd., Church & Dwight Co., Inc., Alpha Pharmaceuticals, Hicks Thermometers India Limited, Reddy’s Laboratories, SMB Corporation of India, Sri Pharmacare.

Based on type, Asia Pacific pregnancy & ovulation testing market is segmented into pregnancy testing (HCG detection) and ovulation testing. The ovulation testing segment is further sub-segmented into ovulation prediction kits and fertility monitors. Additionally, pregnancy testing segment is further sub-segmented into urine-based testing and blood based testing. Based on type of blood test, market is segmented into quantitative and qualitative. Based on product type, market is segmented into pregnancy rapid test kits and ovulation test kits. Pregnancy rapid test kits include linear-indicator devices (strip/dip sticks, cassettes and mid-stream devices) and digital devices. Based on mode of purchase, market is segmented into prescription testing and non-prescription or OTC testing. The non-prescription testing mode of purchase is anticipated to experience significant growth as a result of preference for home pregnancy tests & privacy concerns among women. In addition, based on end-user, market is segmented into pharmacies, gynecology & fertility centers, drug stores, online sales, hospitals & clinics and others.

The Asia Pacific pregnancy & ovulation testing market is driven by emergence in advanced technology with high accuracy, followed by decline in fertility rate, rise in demand for prompt diagnosis, change in lifestyles, increase in prevalence of infertility & gynaecological disorders, unplanned pregnancy rate, increase in awareness of fertility tests, and easy availability of ovulation & pregnancy monitors on e-commerce websites. However, high cost associated with ovulation tests and low adaptation rate may impact the market. Moreover, growth in awareness about pregnancy & ovulation testing is a key opportunity for market.

Based on geography, China holds the most considerable share in Asia Pacific pregnancy & ovulation testing market owing to increase in gynaecological disorders and high population base in the country. The increase in acceptance of home testing kits to check the possibility of pregnancy is estimated to stimulate market demand during the forecast period. It is anticipated that the market will be reached at US $298.68 billion by 2023.

To know more, click on the link below:-

Asia Pacific Pregnancy & Ovulation Testing Market

Contact Us:-

Ken Research

Ankur Gupta, Head Marketing & Communications



Comments are closed.